TreatHF

Apr 9, 2021

What’s new in the 2021 app update:
• New content from the 2021 Update to the 2017 ECDP for Optimization of Heart Failure Treatment, including information regarding use of angiotensin receptor-neprilysin inhibitors (ARNIs) as de novo therapy, and sodium-glucose cotransporter-2 (SGLT2) inhibitors for heart failure.
• Updated app structure for improved user experience
• Updated and expanded Therapy Reference section